Trial · NCT05328102
Adverse events50
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 50
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cytokine release syndrome | Immune system disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Fatigue | General disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Immune effector cell-associated neurotoxicity syndrome | Nervous system disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Skin irritation | Skin and subcutaneous tissue disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Oedema peripheral | General disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Hypervolaemia | Metabolism and nutrition disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Rash | Skin and subcutaneous tissue disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Blood creatinine increased | Investigations | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Hydronephrosis | Renal and urinary disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Pyrexia | General disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Fall | Injury, poisoning and procedural complications | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Asthenia | General disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Hypokalaemia | Metabolism and nutrition disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Hypomagnesaemia | Metabolism and nutrition disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Urinary retention | Renal and urinary disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 1 | 3 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 | |
| other | Urinary tract infection | Infections and infestations | Part 1A: Plamotamab (Lower Dose), Tafasitamab, and Lenalidomide | 2 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05328102/events